Case Report
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 7, 2014; 20(37): 13607-13614
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13607
Table 3 Number and ratio for each reason of donor exclusion during phase II to IV of the living donor evaluation protocol
PhaseStepnExclusionn% from the step
Phase IILiver biopsy371Moderate steatosis164.31
Severe steatosis92.42
Portal tract fibrosis277.27
Bilharzial granuloma102.69
Reactive hepatitis change41.07
Focal portal infiltrate10.26
Portal lymphocyte infiltrate10.26
Hemosiderosis10.26
Focal necrotic areas10.26
301Withdrawal3812.62
Phase IIIVolumetry and anatomical assessment263Portal venous variants20.76
Biliary variants62.28
hepatic venous variants83.04
hepatic venous and biliary variants10.38
hepatic and portal venous variants31.14
Small for size graft155.70
Small residual left lobe41.50
224Withdrawal94.01
Phase IVInformed consent215Withdrawal31.39
Donors underwent surgery212